NVAX SEC Filings
SEC filings for NVAX. Annual and quarterly reports, 8-K events, Form 4 insider filings and 13D/G stake disclosures.
| Form | Filed | Accession |
|---|---|---|
| 10-KAINovavax reports a sharp swing to $440.3M net income on one-time APA termination revenue, steep cost cuts, and new Pfizer and Sanofi partnership milestones, framed optimistically. | Feb 26, 2026 | 0001000694-26-000007EDGAR |
SEC filings for companies related to NVAX
Never miss a NVAX filing.
Get an email when NVAX files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.